<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Estradiol valerate/Dienogest</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08866</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Estradiol valerate/Dienogest is a Combined oral contraceptive (<span class="caps">COC</span>) indicated for use by women to prevent pregnancy. It is also indicated for the treatment of heavy menstrual bleeding in women.</p>
<p>The efficacy of Estradiol valerate/Dienogest in women with a body mass index of <br>
&gt;30 kg/m2 has not been evaluated.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB08866/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB08866/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08866.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08866.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08866.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08866.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08866.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB08866">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>17-hydroxy-3-oxo-19-nor-17&#945;-pregna-4,9-diene-21-nitrile</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>17&#945;-cyanomethyl-17&#946;-hydroxy-estra-4,9(10)-dien-3-one</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>17&#946;-Estradiol-17-valerate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>pentanoate d'estra-1,3,5(10)-tri&#232;ne-3-ol-17&#946;-yle</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Delestrogen</td><td>Bristol Myers-Squibb</td></tr><tr><td>Natazia </td><td>Bayer HealthCare Pharmaceuticals Inc.</td></tr><tr><td>Qlaira</td><td>Bayer HealthCare Pharmaceuticals Inc.</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>65928-58-7</td></tr><tr><th>Weight</th><td>Average: 667.9164<br>Monoisotopic: 667.423673939</td></tr><tr><th>Chemical Formula</th><td>C<sub>43</sub>H<sub>57</sub>NO<sub>5</sub></td></tr><tr><th>InChI Key</th><td>LRHSUZNWLAJWRT-GAJBHWORSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C23H32O3.C20H25NO2/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2;1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3;12,17-18,23H,2-10H2,1H3/t18-,19-,20+,21+,23+;17-,18+,19+,20-/m11/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-[(10S,11S,14R,15S)-14-hydroxy-15-methyl-5-oxotetracyclo[8.7.0.0&#178;,&#8311;.0&#185;&#185;,&#185;&#8309;]heptadeca-1,6-dien-14-yl]acetonitrile (1S,10R,11S,14S,15S)-5-hydroxy-15-methyltetracyclo[8.7.0.0&#178;,&#8311;.0&#185;&#185;,&#185;&#8309;]heptadeca-2(7),3,5-trien-14-yl pentanoate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H].[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB08866.gif?1367173604">show</a>(11.1 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Superclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Class</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Indicated for use by women for pregnancy prevention.
Also indicated for the treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of birth control. </td></tr><tr><th>Pharmacodynamics</th><td>Estradiol valerate is a synthetic prodrug of 17&#223;-estradiol, while dienogest (DNG) is a progestin. DNG displays properties of 19-nortestosterone derivatives as well as properties associated with progesterone derivatives.</td></tr><tr><th>Mechanism of action</th><td>Estradiol valerate/Dienogest lower the risk of becoming pregnant primarily by suppressing ovulation. Additionally, cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation are other possible mechanisms. </td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><p>In serum, 38% of estradiol is bound to sex hormone-binding globulin (<span class="caps">SHBG</span>), 60% to albumin and 2&#8211;3% circulates in free form. An apparent volume of distribution of approximately 1.2 L/kg was determined after intravenous (IV) administration.</p></td></tr><tr><th>Protein binding</th><td>~90%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Estradiol undergoes an extensive first-pass effect and a considerable part of the dose administered is already metabolized in the gastrointestinal mucosa. The CYP 3A family is known to play the most important role in human estradiol metabolism. The main metabolites are estrone and its sulfate or glucuronide conjugates.
Dienogest is extensively metabolized by the known pathways of steroid metabolism (hydroxylation, conjugation), with the formation of mostly inactive metabolites. CYP3A4 was identified as a predominant enzyme catalyzing the metabolism of dienogest.</p></td></tr><tr><th>Route of elimination</th><td>Estradiol and its metabolites are mainly excreted in urine, with about 10% being excreted in the feces.
Dienogest is primarily excreted renally in the form of metabolites and unchanged dienogest is the dominating fraction in plasma.</td></tr><tr><th>Half life</th><td>The terminal half-life of estradiol is approximately 14 hours.
The terminal half-life of dienogest is approximately 11 hours.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9822</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.6267</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5523</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8151</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6719</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5648</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8148</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.811</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8534</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7853</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5521</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6898</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8638</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6985</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6636</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5825</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7683
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9188
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9406
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6442 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8135
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6158
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet, film coated</td><td>Oral</td><td>(dark red) 1 mg estradiol valerate</td></tr><tr><td>Tablet, film coated</td><td>Oral</td><td>(dark yellow) 3 mg estradiol valerate</td></tr><tr><td>Tablet, film coated</td><td>Oral</td><td>(light yellow) 2 mg estradiol valerate and 3 mg dienogest</td></tr><tr><td>Tablet, film coated</td><td>Oral</td><td>(medium red) 2 mg estradiol valerate and 2 mg dienogest</td></tr><tr><td>Tablet, film coated</td><td>Oral</td><td>white tablets (inert), with an embossed &#8220;DT&#8221; in a regular hexagon on one side</td></tr></tbody></table></td></tr><tr><th>Prices</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>144-145</td><td>US. Patent 2,233,025.</td></tr><tr><td>water solubility</td><td>&lt;1 mg/mL</td><td>http://www.eurodiagnostico.com/en/media/pdf/Dienogest.pdf</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>6.17e-04 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>5.28</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>5.78</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-5.8</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>10.33</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>-5.4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>46.53</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>6</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>102.89</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>42.76</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>8</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Miescher, K . and Scholz, C.; U.S. Patent 2,205,627; June 25, 1940; assigned to the Society<br>
of Chemical Industry in Basle, Switzerland.<br>
Miescher, K. and Scholz, C.; U.S. Patent 2,233,025; February 25,1941; assigned to Ciba<br>
Pharmaceutical Products, Incorporated.</p></span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Whalen KL, Rose R: Estradiol valerate/dienogest: a novel oral contraceptive. Ann Pharmacother. 2011 Oct;45(10):1256-61. doi: 10.1345/aph.1Q216. Epub 2011 Sep 13. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21917554">Pubmed</a></li>
	<li>Wasiak R, Filonenko A, Vanness DJ, Law A, Jeddi M, Wittrup-Jensen KU, Stull DE, Siak S, Jensen JT: Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding. J Womens Health (Larchmt). 2013 Apr;22(4):378-84. doi: 10.1089/jwh.2012.3633. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23586801">Pubmed</a></li>
	<li>Ruan X, Seeger H, Mueck AO: The pharmacology of dienogest. Maturitas. 2012 Apr;71(4):337-44. doi: 10.1016/j.maturitas.2012.01.018. Epub 2012 Feb 24. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22364708">Pubmed</a></li>
	<li>Fraser IS, Jensen J, Schaefers M, Mellinger U, Parke S, Serrani M: Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest. Contraception. 2012 Aug;86(2):96-101. doi: 10.1016/j.contraception.2011.11.011. Epub 2012 Jan 10. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22240178">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D01413" target="_blank">D01413 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/natazia-drug.htm" target="_blank">http://www.rxlist.com/natazia-drug.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/natazia.html" target="_blank">http://www.drugs.com/natazia.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>AHFS Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB08866.pdf?1367176039">show</a>(599 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB08866.pdf?1367176015">show</a>(568 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00559">Bosentan</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB00625">Efavirenz</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB00607">Nafcillin</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB00238">Nevirapine</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB04938">Ospemifene</a></td><td>Pharmacodynamic synergist; contraindicated. </td></tr><tr><td><a href="/drugs/DB00312">Pentobarbital</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB00794">Primidone</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB01201">Rifapentine</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Grapefruit juice may increase plasma concentrations of dienogest. (CYP3A4 inhibitor)</li></ul></td></tr></tbody></table>